by Gemma Escarré,
Ysios Capital, venture capital firm specialised in life sciences and member of CataloniaBio & HealthTech, announced that it has appointed Guillem Laporta as Principal and Claudia D’Augusta and Lance Berman as new Venture Partners to strengthen the strategic area and analysis, as well as international projection.
Laporta started his career at Caixa Capital Risc. Since 2013 was Associate at Edmond de Rothschild group (now Andera Partners).
D'Augusta has an extensive experience in the financial management of biotechnology companies and currently is General Manager at TiGenix. Prior to joining Ysios, Berman was CMO and Senior Vice President at Relypsa in the San Francisco Bay area where he was responsible for building and leading the company’s clinical development, medical affairs and drug safety functions.
Ysios Capital was founded in 2008 and currently manages about €200 million distributed across two funds: Ysios BioFund I, fully invested, and Ysios BioFund II Innvierte, that in 2018 will make its thirteenth and last investment.
Photo: Form left to right, Guillem Lapota, Claudia D'Augusta and Lance Berman - © Ysios Capital